dulaglutide vs semaglutide weight loss Key drivers of clinical differences between once-weekly and GLP-1 Medications: Ozempic vs. Trulicib – Semaglutide vs. dulaglutide for glycemic

The exciting news

To meet the diagnostic criteria for cEDS, a person must meet: Major criterion 1 AND major criterion 2 OR Major criterion 1 AND three or more minor criteria Major Criteria Skin hyperextensibility and atrophic scarring Generalized joint hypermobility Minor Criteria Easy bruising Soft, doughy skin Skin fragility (or traumatic splitting) Molluscoid pseudotumors Subcutaneous spheroids Hernia (or history thereof) Epicanthal folds Complications of joint hypermobility (e.g., sprains, dislocations/subluxations, pain, flexible flatfoot) Family history of a first-degree relative who meets clinical criteria Genetic testing is used to see if a person has a genetic variant that causes vEDS

Reported effects are generally mild injection-site reactions, fatigue, lightheadedness after a dose

Novos Rybelsus sales were approximately $3.5 billion in 2025

For men and women seeking sustainable fat loss, our medical weight loss programs combine GLP-1 peptide therapy with a personalized nutrition and exercise strategy to support long-term results